• etrials Worldwide (Morrisville, North Carolina) said that MacuSight has selected etrials' Trial Intelligence electronic data capture (EDC) and etrials' Site Intelligence IVR solutions as the central component of its clinical data management process, playing a key role in helping MacuSight to glean actionable information from its clinical trial data, thereby enhancing and accelerating decision-making. etrials Worldwide is a leading provider of adaptive eClinical software and services that optimize clinical trial management by turning data into intelligence and shortening the pathway to an actionable study endpoint. MacuSight is a privately-held pharmaceutical company that is focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions.

• ExpressMD Solutions (Berkeley Heights, New Jersey) said that its remote patient health monitoring system has received 510(k) market clearance from the FDA. ExpressMD plans to initiate manufacturing and sales of its Electronic House Call monitoring devices and services immediately. The Electronic House Call System will be used by healthcare professionals who manage patients with chronic conditions, such as heart disease, COPD (Chronic Obstructive Pulmonary Disease) and diabetes. Patients are able to use the monitoring devices located in their home to measure their vital signs and to motivate them through education and reminders. The Electronic House Call monitor securely transmits this information to its data center making it conveniently available to each licensed care provider via a secure website. By remotely receiving patient data daily, licensed care providers can adjust treatment accordingly and provide an enhanced level of care.

• TheraDoc (Salt Lake City) has introduced a new patient safety surveillance tool to help hospitals address a recent Joint Commission National Patient Safety Goal focused on reducing the possibility of patient harm associated with anticoagulation therapy. The TheraDoc Anticoagulation Alerts package tracks the condition of patients receiving anticoagulation drug therapy to prevent blood clots, providing an early warning of potential adverse drug events or other problems. Anticoagulation therapy is a high-risk treatment, and adverse events are common due to dosing complexity and difficulties in monitoring the drugs' safety and efficacy.

No Comments